Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Trials. 2010 Oct;7(5):546-56. doi: 10.1177/1740774510372657. Epub 2010 Jun 22.

A Bayesian adaptive design with biomarkers for targeted therapies.

Author information

  • 1Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA. eickhoff@biostat.wisc.edu

Abstract

BACKGROUND:

Targeted therapies are becoming increasingly important for the treatment of various diseases. Biomarkers are a critical component of a targeted therapy as they can be used to identify patients who are more likely to benefit from a treatment. Targeted therapies, however, have created major challenges in the design, conduct, and analysis of clinical trials. In traditional clinical trials, treatment effects for various biomarkers are typically evaluated in an exploratory fashion and only limited information about the predictive values of biomarkers obtained.

PURPOSE:

New study designs are required, which effectively evaluate both the diagnostic and the therapeutic implication of biomarkers.

METHODS:

The Bayesian approach provides a useful framework for optimizing the clinical trial design by directly integrating information about biomarkers and clinical outcomes as they become available. We propose a Bayesian covariate-adjusted response-adaptive randomization design, which utilizes individual biomarker profiles and patient's clinical outcomes as they become available during the course of the trial, to assign the most efficacious treatment to individual patients. Predictive biomarker subgroups are determined adaptively using a partial least squares regression approach.

RESULTS:

A series of simulation studies were conducted to examine the operating characteristics of the proposed study design. The simulation studies show that the proposed design efficiently identifies patients who benefit most from a targeted therapy and that there are substantial savings in the sample size requirements when compared to alternative designs.

LIMITATIONS:

The design does not control for the type I error in the traditional sense and a positive result should be confirmed by conducting an independent phase III study focusing on the selected biomarker profile groups.

CONCLUSIONS:

We conclude that the proposed design may serve a useful role in the early efficacy phase of targeted therapy development.

PMID:
20571131
[PubMed - indexed for MEDLINE]
PMCID:
PMC3788617
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk